Vanda Pharmaceuticals Inc.·4

Feb 24, 4:28 PM ET

Honore Tage 4

4 · Vanda Pharmaceuticals Inc. · Filed Feb 24, 2026

Research Summary

AI-generated summary of this filing

Updated

Vanda (VNDA) Director Honore Tage Sells 30,000 Shares

What Happened
Honore Tage, a director of Vanda Pharmaceuticals, reported the sale of 30,000 shares on Feb 23, 2026. The shares were disposed at $8.03 each for a total transaction value of $240,900. The Form 4 lists the transaction as a sale (code S), reported as an open-market or private sale.

Key Details

  • Transaction date: 2026-02-23; Price: $8.03 per share; Total value: $240,900.
  • Transaction type: Sale (S) — reported as open-market or private sale.
  • Shares owned after the transaction: not disclosed in the information provided in this summary.
  • No 10b5-1 trading plan, tax-withholding, or other footnotes were indicated in the supplied data.
  • Filing date: 2026-02-24 — one day after the transaction; this appears to be a timely Form 4 filing.

Context
Sales by directors are common and can be driven by diversification, liquidity needs, or pre-planned arrangements; they are not, by themselves, definitive indicators of company performance. For retail investors, purchases typically carry more direct informational weight than routine sales.

Insider Transaction Report

Form 4
Period: 2026-02-23
Honore Tage
Director
Transactions
  • Sale

    Common Stock

    2026-02-23$8.03/sh30,000$240,90093,469 total
Signature
/s/ Tage Honore|2026-02-24

Documents

1 file
  • 4
    ownership.xmlPrimary

    4